FDA Updates Guidelines on GLP-1 Compounding Post-Shortage
The FDA has revised guidelines on GLP-1 drug compounding post-shortage resolution.
Why it matters: Non-compliance can disrupt pharmacy operations and lead to regulatory scrutiny, affecting legal accountability.
- Compounders can produce drug copies only if on FDA's shortage list.
- Semaglutide and tirzepatide shortages expected to be resolved by February 2025.
- Compounders have 60-day (503A) and 90-day (503B) compliance periods post-shortage.
- FDA will enforce actions against non-approved, mass-marketed GLP-1 products.
The FDA has updated its guidelines on compounding GLP-1 drugs, crucial for managing diabetes. "Compounding" involves creating drug formulations tailored to specific patient needs, which are not commercially available. The guidelines differentiate between two types of compounding facilities: section 503A, which applies to traditional pharmacies, and section 503B, for larger outsourcing facilities.
Following the anticipated resolution of semaglutide and tirzepatide shortages by February 2025, the FDA expects these facilities to only compound drugs listed in their shortage database. This move aims to prevent shortages and ensure the availability of essential medications in future.
Pharmacies have a grace period—60 days for traditional compounding (503A) and 90 days for outsourcing facilities (503B)—to adjust to the new regulations once a drug is no longer on the shortage list. Previously, companies like Hims & Hers had responded to demand spikes by distributing compounded GLP-1 products.
Additionally, the FDA plans to enforce against companies marketing non-FDA-approved GLP-1 products to curb unauthorized sales. Pharmacies must now ensure compliance with these guidelines to avoid potential compliance issues that could arise from regulatory scrutiny.
By the numbers:
- 503A and 503B — FDA sections outlining traditional and outsourcing compounding regulations.
- February 2025 — Expected resolution of semaglutide and tirzepatide shortages.
- 60 and 90 days — Compliance periods for 503A and 503B facilities, respectively.
Yes, but: Some pharmacies may face operational challenges in adjusting to the new guidelines promptly.
What's next: Pharmacies will monitor FDA's shortage list and adjust operations accordingly by early 2025.